# Chronic kidney disease 4<sup>th</sup> years

**Mohammad Hassan Al-thnaibat** 

## Outline

- Basics about the kidney
- Kidney functions
- GFR (estimation versus measurement)
- Pathophysiology of kidney disease
- CKD definition/ stages
- Epidemiology/Jordan
- Manifestation
- Complication
- Management (headlines)

# Kidney

- Kidney 150 gm (heart 300 mg), 12 cm length (left kidney larger than right)
- 1.3 million nephrons each kidney (fixed number, completed early in life)
- 2 types of nephrons
- Cortical 85%: short loop of Henle
- Juxtamedullary: long loop of Henle with Vasa recta, participate in concentration of urine



# **Kidney functions**

- Regulation of fluid, pH, BP (short term = RAAS or long term = blood volume)
- Homeostasis of electrolytes
- Endocrine (3 hormones RAAS, activation of Vitamin D, Erythropoietin 85%) Paracrine (PG E2, NO)
- Clearance: Excretion (endogenous or exogenous waste)
- Gluconeogenesis 10% (fasting)



#### **GFR** (estimation versus measurement)

- Constant production
- Freely filtered at the glomerulus
- No tubular secretion or resorption
  - Some tubular secretion X
- No extra-renal metabolism
- No extra-renal loss
  - Some GIT loss X
- Loss of creatinine through avenues other than glomerular filtration means Creatinine Clearance is slightly higher than the GFR

#### Other filtration marker (exogenous)

#### BOX 1

#### Examples of Common Glomerular Filtration Markers

#### Radionuclides

- Inulin labeled with carbon 14 (<sup>14</sup>C-inulin)
- Technetium Tc 99m diethylenetriaminepentaacetic acid (<sup>99m</sup>Tc-DTPA)
- Chromium Cr 51 ethylenediaminetetraacetic acid (<sup>51</sup>Cr-EDTA)

#### Nonradionuclides

- Iodinated
  - -lonic: lothalamate
  - -Nonionic: lohexol, iopamidol
- Noniodinated
  - —Inulin
  - —Creatinine (endogenous or exogenously administered)

### **CKD** definition

- Progressive irreversible loss of kidney functions
- Before 2002 (KDOQI): chronic renal failure
- <u>Structural or functional</u> abnormalities of the kidneys for <u>>3 months</u>, with or without decreased GFR < 60.</li>
- NICE UK 2008 : stage 3 a and b
- KDIGO 2012: A1-A3

# Pathophysiology

- Started by initiating injury
- Recruit inflammatory cell
- Release growth factor (balance between good and bad)
- Metalloproteinase, PA (cut the collagen)
- RAAS system activation: Ag II pro fibrotic

#### **CKD** stages



UNDER-DIAGNOSED CHRONIC KIDNEY DISEASE IN JORDANIAN ADULTS: PREVALENCE AND CORRELATES

Amani A. Khalil 👩<sup>7</sup>, Mona A. Abed<sup>2</sup>, Muayyad Ahmad<sup>4</sup>, Ayman Hamdan Mansowr<sup>3</sup> <sup>1</sup>School of Nursing, The University of Jordan, Amman, Jordan <sup>2</sup>Faculty of Nursing, Hashemite University, Zarga, Jordan

# Epidemiology

- 10% of the adult population around the world have CKD stages 1–5
- Registration and diagnosis (variable between countries)
- found that approximately 31% of the individuals (at high risk) had unrecognised CKD eGFR < 90.</li>
- 7% of the present sample had an eGFR of
- Mortality is higher than non CKD



### **Risk factors**

- Individuals with any of the following attributes are at high risk for CKD and could benefit from screening:
- 1- age more than 60 years
- 2- Diabetes mellitus (DM)
- 3- Hypertension (HTN)
- 4- Family history of kidney diseases

# Leading causes of CKD

- 1- Diabetes
- 2- Hypertension
- 3- Obstructive nephropathy (kidney stones, BPH)
- 4- Kidney diseases (TIN, GN, ADPKD, recurrent UTI and pyelonephritis)
- 5- Renovascular diseases
- 6- Some medications for example, NSAIDs, Heavy metals
- 7- Fetal developmental problem
- 8- Infections like Hep C and HIV, Malaria and yellow fever
- 9- Illegal substance abuse such as heroin or cocaine.

Injury - a sharp blow or physical injury to the kidney

### **Clinical manifestation**

#### • Urinary:

- Urine output: polyuria, oliguria, anuria
- Frothy, hematuria
- Uremia: accumulation of waste product (protein metabolism)
- Volume: hypervolemia
- Acid base, electrolytes:
- Sodium
- Potassium
- Acidosis
- Ca
- Phosphate

#### Hematological

- Anemia
- Bleeding: platelets dysfunction
- Infection:
- CVS: CAD, HF, LVH, arrhythmia, pericarditis
- RS: pulmonary edema
- **GI:** N/V, ulcer, uremic fetor
- Neuro: encephalopathy, peripheral neuropathy, restless leg syndrome

- Skin
- Earthy color
- Pruritus
- Petechiae, ecchymosis
- Nail changes

#### **Uremic Forest**















# Investigation

- Urea/Cr
- Urinalysis and quantification of proteinuria;
- Electrolytes; hyperkalaemia and acidosis, Calcium, phosphate, parathyroid hormone; Albumin
- Full blood count (± Fe, ferritin, folate, B12);
- Lipids, glucose ± HbA1c;
- Renal ultrasound: size, asymmetry, cyst
- Hepatitis and HIV serology
- ECG
- SPEP, serological test

## Management

- Acute versus chronic (baseline)
- Reversibility
- Retard progression
- Treat complication
- Prepare for renal replacement therapy



#### AKI or CKD

	Acute Kidney Injury	Chronic Kidney Disease
History	Short duration History of acute illness	Long duration History of kidney disease and/ or causative co-morbidity
Examination	Acutely ill May have hypotension, fluid overload, metabolic acidosis,	Better toleration of biochemical abnormalities Anaemia, cachexia, grey discolouration of skin
Creatinine Calcium	Rapidly increasing values Usually normal	History indicating derangement Stable serial measurements Low in untreated chronic disease
Haemoglobin	May be normal or low	Due to erythropoietin deficiency- chronic normocytic anaemia
Renal ultrasound	Often normal When the cause is acute obstruction- hydronephrosis	Scars from reflux nephropathy Renovascular disease- asymmetry Large kidneys in • Diabetes, • Amyloidosis, • Chronic Hydropnephrosis • Polycystic Kidney disease
		Adapted from Hall (2008

### Treat the cause

- GN
- Pyelonephritis
- AIN
- Obstruction
- Renovascular disease

### Progression

- BP
- Glycemic control
- RAAS blocker
- SGLT2 inhibitors
- Stop smoking
- Diet: protein, salt, phosphate, K
- Exercise
- Obesity
- Acidosis HCO3 < 22
- Uric acid ?
- Dyslipidemia

Table 33-4	Drug Dosages in Chronic	
	Kidney Disease	

Major Dosage Reduction	Minor or No Reduction	Avoid Usage
Antibiotics		
Aminoglycosides Penicillin Cephalosporins Sulfonamides Vancomycin Quinolones Fluconazole Acyclovir,	Erythromycin Nafcillin Clindamycin Chloramphenicol Isoniazid, rifampin Amphotericin B Aztreonam, tazobactam Doxycycline	Nitrofurantoin Nalidixic acid Tetracycline
ganciciovir Foscarnet Imipenem		
Others		
Digoxin Procainamide H <sub>2</sub> antagonists Meperidine Codeine Propoxyphene	Antihypertensives Benzodiazepines Quinidine Lidocaine Spironolactone Triamterene	Aspirin Sulfonylureas Lithium carbonate Acetazolamide NSAIDs Phosphate- containing bawel propr

#### Complication

- Treat anemia target (10-11)
- Secondary hyperparathyroidism
- CV disease



#### RRT

- Transplant
- Hemodialysis
- Peritoneal dialysis
- Artificial kidney
- Animal kidney ?